Mitsubishi Tanabe Obtains Right To Kidney Drug From Canadian Cytochroma
This article was originally published in PharmAsia News
Executive Summary
Mitsubishi Tanabe Pharmaceutical announced July 30 it signed a licensing agreement and obtained exclusive rights to develop and market CTA018 in the U.S. and Asia including Japan with Cytochroma, a Canadian bio-venture company. CTA018 is a vitamin D analog used to treat secondary hyperparathyroidis in patients with chronic kidney disease, and is entering Phase II development in Canada. According to the company, CTA018 is more effective in lowering parathormone compared to the current vitamin D analog. Cytochroma could receive up to CDN$105 million in up-front payments, milestone payments and an equity investment. (Click here for more - Japanese language